These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 20688025)

  • 1. Deferasirox induced liver injury in haemochromatosis.
    Aslam N; Mettu P; Marsano-Obando LS; Martin A
    J Coll Physicians Surg Pak; 2010 Aug; 20(8):551-3. PubMed ID: 20688025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deferasirox induced liver injury in haemochromatosis.
    Imran FS; Phatak P
    J Coll Physicians Surg Pak; 2011 Nov; 21(11):718; author reply 718. PubMed ID: 22078360
    [No Abstract]   [Full Text] [Related]  

  • 3. Deferasirox (Exjade): a new iron chelator.
    Med Lett Drugs Ther; 2006 Apr; 48(1233):35-6. PubMed ID: 16625144
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety of deferasirox: a retrospective cohort study on the risks of gastrointestinal, liver and renal events.
    Huang WF; Chou HC; Tsai YW; Hsiao FY
    Pharmacoepidemiol Drug Saf; 2014 Nov; 23(11):1176-82. PubMed ID: 24946110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute renal failure and Fanconi syndrome due to deferasirox.
    Grangé S; Bertrand DM; Guerrot D; Eas F; Godin M
    Nephrol Dial Transplant; 2010 Jul; 25(7):2376-8. PubMed ID: 20466673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemojuvelin hemochromatosis receiving iron chelation therapy with deferasirox: improvement of liver disease activity, cardiac and hematological function.
    Maeda T; Nakamaki T; Saito B; Nakashima H; Ariizumi H; Yanagisawa K; Hattori A; Tatsumi Y; Hayashi H; Suzuki K; Tomoyasu S
    Eur J Haematol; 2011 Nov; 87(5):467-9. PubMed ID: 21848699
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.
    Spellberg B; Andes D; Perez M; Anglim A; Bonilla H; Mathisen GE; Walsh TJ; Ibrahim AS
    Antimicrob Agents Chemother; 2009 Jul; 53(7):3122-5. PubMed ID: 19433555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical application of deferasirox: practical patient management.
    Vichinsky E
    Am J Hematol; 2008 May; 83(5):398-402. PubMed ID: 18058997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastric ulcer in a child treated with deferasirox.
    Bauters T; Mondelaers V; Robays H; Hunninck K; de Moerloose B
    Pharm World Sci; 2010 Apr; 32(2):112-3. PubMed ID: 20063122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron chelation with deferasirox in two patients with HFE hemochromatosis and chronic anemia.
    Nagler M; Gregor M; Wuillemin WA
    Acta Haematol; 2011; 126(2):119-21. PubMed ID: 21659727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral iron chelator deferasirox in the treatment of secondary hemochromatosis following bone marrow transplantation in a patient with severe aplastic anemia.
    Quarta A; Melpignano A; Quarta G
    Acta Haematol; 2011; 125(4):219-21. PubMed ID: 21266801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comment to: Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox. Haematologica 2008;93:e9-10.
    Ford JM; Rojkjaer L
    Haematologica; 2008 Jun; 93(6):e49; discussion e50. PubMed ID: 18515872
    [No Abstract]   [Full Text] [Related]  

  • 13. Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox (ICL670) at the Pediatric Clinic in Monza, Italy.
    Masera N; Rescaldani C; Azzolini M; Vimercati C; Tavecchia L; Masera G; De Molfetta V; Arpa P
    Haematologica; 2008 Jan; 93(1):e9-10. PubMed ID: 18166775
    [No Abstract]   [Full Text] [Related]  

  • 14. Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous β-thalassaemia.
    Allegra S; De Francia S; Longo F; Massano D; Cusato J; Arduino A; Pirro E; Piga A; D'Avolio A
    Biomed Pharmacother; 2016 Dec; 84():1510-1512. PubMed ID: 27881236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful desensitization to deferasirox in a paediatric patient with β-Thalassaemia major.
    Davies GI; Davies D; Charles S; Barnes SL; Bowden D
    Pediatr Allergy Immunol; 2017 Mar; 28(2):199-201. PubMed ID: 27797415
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety and efficacy of deferasirox in multitransfused Indian children with β-thalassaemia major.
    Chandra J; Chaudhary H; Pemde H; Singh V; Dutta AK
    Ann Trop Paediatr; 2011; 31(1):47-51. PubMed ID: 21262109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperchloraemic metabolic acidosis induced by the iron chelator deferasirox: a case report and review of the literature.
    Dell'Orto VG; Bianchetti MG; Brazzola P
    J Clin Pharm Ther; 2013 Dec; 38(6):526-7. PubMed ID: 23981248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deferasirox-induced serious adverse reaction in a pediatric patient: pharmacokinetic and pharmacogenetic analysis.
    Marano M; Bottaro G; Goffredo B; Stoppa F; Pisani M; Marinaro AM; Deodato F; Dionisi-Vici C; Clementi E; Falvella FS
    Eur J Clin Pharmacol; 2016 Feb; 72(2):247-8. PubMed ID: 26403473
    [No Abstract]   [Full Text] [Related]  

  • 19. Lactose intolerance is not the cause of gastrointestinal adverse effects in beta thalassemia patients treated with deferasirox.
    Pazgal I; Brown M; Perets TT; Niv Y; Rachmilewitz E; Stark P
    Am J Hematol; 2014 Sep; 89(9):938-9. PubMed ID: 24923845
    [No Abstract]   [Full Text] [Related]  

  • 20. Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major.
    Papadopoulos N; Vasiliki A; Aloizos G; Tapinis P; Kikilas A
    Ann Pharmacother; 2010 Jan; 44(1):219-21. PubMed ID: 19934389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.